Stereotactic body radiation therapy for patients with lung and liver oligometastases from colorectal cancer: a phase Ⅱ trial.
10.3760/cma.j.cn112152-20200413-00339
- VernacularTitle:立体定向放射技术治疗结直肠癌肝与肺寡转移的Ⅱ期临床研究
- Author:
Jun Qin LEI
1
;
Wen Yang LIU
1
;
Yuan TANG
1
;
Yu TANG
1
;
Ning LI
1
;
Hua REN
2
;
Chi YIHEBALI
3
;
Yong Kun SUN
3
;
Wen ZHANG
3
;
Xin Yu BI
4
;
Jian Jun ZHAO
4
;
Hui FANG
1
;
Ning Ning LU
1
;
Ai Ping ZHOU
3
;
Shu Lian WANG
1
;
Yong Wen SONG
1
;
Yue Ping LIU
1
;
Bo CHEN
1
;
Shu Nan QI
1
;
Jian Qiang CAI
4
;
Ye Xiong LI
1
;
Jing JIN
1
Author Information
1. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Hospital, Shenzhen 518116, China.
3. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
4. Department of Abdominal Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Oligometastases;
Stereotactic body radiation therapy
- MeSH:
Colorectal Neoplasms;
Humans;
Liver/pathology*;
Lung/pathology*;
Prospective Studies;
Radiosurgery/methods*
- From:
Chinese Journal of Oncology
2022;44(3):282-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the safety and effectiveness of stereotactic body radiation therapy (SBRT) for oligometastases from colorectal cancer (CRC). Methods: This is a prospective, single-arm phase Ⅱ trial. Patients who had histologically proven CRC, 1 to 5 detectable liver or lung metastatic lesions with maximum diameter of any metastases ≤5 cm were eligible. SBRT was delivered to all lesions. The primary endpoint was 3-year local control (LC). The secondary endpoints were treatment-related acute toxicities of grade 3 and above, 1-year and 3-year overall survival (OS) and progression free survival (PFS). Survival analysis was performed using the Kaplan-Meier method and Log rank test. Results: Petients from 2016 to 2019 who were treated in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Forty-eight patients with 60 lesions were enrolled, including 37 liver lesions and 23 lung lesions. Forty-six patients had 1 or 2 lesions, with median diameter of 1.3 cm, the median biologically effective dose (BED(10)) was 100.0 Gy. The median follow-up was 19.5 months for all lesions. Twenty-five lesions developed local failure, the median local progression free survival was 15 months. The 1-year LC, OS and PFS was 70.2% (95% CI, 63.7%~76.7%), 89.0% (95% CI, 84.3%~93.7%) and 40.4% (95%CI, 33.0%~47.8%). The univariate analysis revealed that planning target volume (PTV) and total dose were independent prognostic factors of LC (P<0.05). For liver and lung lesions, the 1-year LC, OS and PFS was 58.7% and 89.4% (P=0.015), 89.3% and 86.5% (P=0.732), 30.5% and 65.6% (P=0.024), respectively. No patients developed acute toxicity of grade 3 and above. Conclusion: SBRT is safe and effective treatment method for oligometastases from CRC under precise respiratory motion management and robust quality assurance.
